Melbourne, Australia-based Adherium, a digital health company that focuses in improving medication adherence and patient outcomes, has just received FDA clearance for a new inhaler monitoring device ...

Harvard Pilgrim Health Care has entered into its third outcomes-based pharmaceutical contract tying what it pays for drugs to how well the patient does on the medicine. In its most recent agreement, ...

Smart inhaler company Adherium announced last week that it has received 510(k) clearance for over-the-counter sales of its inhaler monitoring device for AstraZeneca’s Symbicort aerosol inhaler, called ...

AstraZeneca announced in its first-quarter presentation (PDF) on Tuesday that it had stopped working on a phase 1 Alzheimer's disease drug and two phase 2 programs for migraine and osteoarthritis pain ...

SAN FRANCISCO (MarketWatch) -- AstraZeneca PLC said Monday that results from a one-year study show that patients taking its Symbicort single-inhaler therapy had fewer asthma attacks and required less ...

On Friday, AstraZeneca Plc (NASDAQ:AZN) reported topline data from Phase 3 KALOS and LOGOS trials in patients with uncontrolled asthma. KALOS and LOGOS trials ...

(Reuters) -AstraZeneca breached the UK pharmaceutical industry's code of practice after a website claim incorrectly stated that all newly diagnosed asthma patients aged 12 and above should receive its ...

Pittsburgh-based Highmark Health signed an outcomes-based contract with drugmaker AstraZeneca for its asthma and chronic obstructive pulmonary disease drug Symbicort. The contract will apply to ...